scholarly journals Characteristics of Giant Cell Tumor of the Bone in Pediatric Patients: Our 18-Year, Single-Center Experience

Children ◽  
2021 ◽  
Vol 8 (12) ◽  
pp. 1157
Author(s):  
Woo-Jong Kim ◽  
Sungmin Kim ◽  
Dae-Woong Choi ◽  
Gil-Hwan Lim ◽  
Sung-Taek Jung

A giant cell tumor (GCT) of the bone is characteristically found in skeletally mature patients. The tumor is rare in pediatric patients, and incidence reported in literature varies from 1.8% to 10.6%. We performed a retrospective study addressing symptoms, treatment, and outcome in pediatric patients who were diagnosed with GCT between March 1997 and January 2015 at our hospital. Fourteen (11.1%) of 126 surgically treated patients with histologically proven GCT were <19 years of age. We confirmed skeletal maturity using magnetic resonance imaging (MRI). Fourteen patients from 8 to 19 years old were identified. Sixteen lesions (76.2%) were found in long bones and 5 lesions (23.8%) in short bones. The most common site was around the knee in 8 patients (38%). GCTs mostly occur at the epi-metaphysis in 11 patients (52.3%). Regardless of the openness of epiphyseal plate, we observed GCT of bone in the epiphysis. Further study will be needed to prove the association between the presence of epiphyseal plate and location of tumor. Three patients (21.4%) had multicentric lesions, and four patients (28.5%) had local recurrence. Multicentric giant cell tumor and local recurrence occur more often in pediatric patients. The characteristics of GCT in pediatric patients do not differ from what is reported for GCT in adults.

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Michele Gaeta ◽  
Giuseppe Cicero ◽  
Luca Fiorillo ◽  
Sergio Vinci ◽  
Alfredo Blandino ◽  
...  

Giant cell tumor of the tendon sheath is a tumor, which affects mainly the hands of people aged 30 to 50 years with a female prevalence. Magnetic resonance imaging (MRI) is essential for diagnosis and treatment planning. The aim of this study is to evaluate the efficacy of multiecho gradient-echoes (MeGE) sequence in detecting hemosiderin which is the hallmark of this tumor. MRIs were performed in a sample of 11 patients with a mean age of 45. With the proposed protocol, all readers were able to detect the susceptibility artifacts due to the presence of hemosiderin. MeGE sequence allows to highlight the presence of hemosiderin, and the use of 3 echo times (ET) (8, 16, and 24 ms) is suggested.


2021 ◽  
pp. 100366
Author(s):  
Lenian Zhou ◽  
Shanyi Lin ◽  
Hanqiang Jin ◽  
Zhaoyuan Zhang ◽  
Changqing Zhang ◽  
...  

Author(s):  
Kenta Hayashida ◽  
Yusuke Kawabata ◽  
Ikuma Kato ◽  
Takayuki Kamiishi ◽  
Kosuke Matsuo ◽  
...  

2005 ◽  
Vol &NA; (438) ◽  
pp. 116-122 ◽  
Author(s):  
Richard L McGough ◽  
Janie Rutledge ◽  
Valerae O Lewis ◽  
Patrick P Lin ◽  
Alan W Yasko

2021 ◽  
Author(s):  
taojun gong ◽  
Yi Luo ◽  
Yitian Wang ◽  
Chuanxi Zheng ◽  
Jianguo Fang ◽  
...  

Abstract Background: Giant cell tumor of bone (GCTB) is a rare benign but locally aggressive bone tumor. It has a high tendency for local recurrence, which may increase the occurrence of lung metastasis. Currently, the treatment of pulmonary metastases of GCTB is controversial. Denosumab is the preferred regimen for unresectable metastatic lesions, but there are no alternative treatment options when denosumab is resistant. So far, no case reports of metastatic GCTB treated with denosumab and apatinib have been published. Case presentation: This is a case report of a 26-year-old female who experienced right knee pain for over 6 months. Radiography and computed tomography revealed osteolytic bony destruction in the proximal right tibia. Using histological, radiological, and clinical techniques, a diagnosis of GCTB was achieved. Meanwhile, the immunohistochemical stain-identified the tumor cells were positive for vascular endothelial growth factor receptor 2 (VEGFR-2). After intralesional curettage of the primary tumor and wide resection of local recurrence surgeries, she developed recurrent hemoptysis. Chest computed tomography (CT) images showed multiple pulmonary nodules. She was administrated denosumab therapy but disease progression was confirmed after four months of treatment. She then received denosumab and apatinib therapy for 24 months, after a partial response was achieved.Conclusions: We depict a case of multiple pulmonary metastases of GCTB successfully controlled by denosumab and apatinib therapy. VEGFR-2 may be an effective therapeutic target for GCTB with pulmonary metastasis when denosumab is ineffective.


2019 ◽  
Vol Volume 11 ◽  
pp. 669-680 ◽  
Author(s):  
Mingmin Shi ◽  
Lei Chen ◽  
Yangxin Wang ◽  
Wei Wang ◽  
Yujie Zhang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document